Ivabradine
Key Points
- Ivabradine is an If-current inhibitor used as adjunct therapy in selected stable HFrEF pathways.
- The drug lowers heart rate by acting on sinoatrial pacemaker current and prolonging diastolic filling time.
- Typical dosing is 5-7.5 mg orally twice daily with food.
- Important risks include bradycardia, atrial fibrillation, heart block, QT prolongation/torsade risk, and visual luminous phenomena.
- Contraindications include acute decompensated heart failure, hypotension, significant conduction disease, bradycardia, liver dysfunction, and pregnancy.
- Grapefruit and CYP-mediated interaction burden (for example verapamil/diltiazem pathways) requires focused reconciliation.
Pathophysiology
Ivabradine selectively inhibits the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel that carries the If pacemaker current in the sinoatrial node. Slowing this pacemaker current reduces heart rate without primary inotropic suppression.
Lower heart rate reduces myocardial oxygen demand and extends diastole, which can improve coronary perfusion timing in selected chronic heart-failure contexts.
Nursing Assessment
NCLEX Focus
Confirm hemodynamic stability before dosing; ivabradine is not used in acute decompensated heart-failure states.
- Assess baseline heart rate, blood pressure, rhythm history, and current heart-failure status.
- Screen for contraindications: acute decompensated HF, symptomatic hypotension, significant bradycardia, conduction disease, hepatic dysfunction, and pregnancy.
- Assess for current AF burden, conduction abnormalities, or QT-risk history before initiation.
- Reconcile interacting medications, including CYP-modifying agents and concurrent nodal-rate-slowing drugs.
Nursing Interventions
- Administer with food and keep dosing schedule consistent.
- Monitor for bradycardia, dizziness, lightheadedness, dyspnea, palpitations, or irregular heartbeat.
- Monitor rhythm trends for new atrial fibrillation or conduction worsening.
- Teach patients to avoid grapefruit juice and to report visual brightness/halo phenomena that interfere with safety.
- Reinforce pregnancy avoidance and immediate reporting of possible pregnancy.
Decompensation and Rhythm Risk
Ivabradine should not be used during acute decompensated HF and can precipitate clinically important bradyarrhythmia/atrial-fibrillation events.
Pharmacology
| Drug/Class | Typical Dose | Key RN Considerations |
|---|---|---|
| Ivabradine (If-current inhibitor) | 5-7.5 mg PO twice daily (max 7.5 mg BID) | Give with food; monitor HR/BP/rhythm; avoid grapefruit; assess pregnancy and conduction contraindications |
Clinical Judgment Application
Clinical Scenario
A stable HFrEF patient on optimized first-line therapy still has persistent symptoms and is started on ivabradine.
- Recognize Cues: Persistent symptomatic burden despite optimized baseline HF medications.
- Analyze Cues: Adjunct heart-rate reduction may improve oxygen demand-filling balance.
- Prioritize Hypotheses: Main risks are bradycardia, rhythm disturbance, and intolerance.
- Generate Solutions: Plan close HR/BP/rhythm follow-up and interaction review.
- Take Action: Start medication with food, reinforce grapefruit/pregnancy teaching, and monitor adverse cues.
- Evaluate Outcomes: Symptoms and tolerance improve without hemodynamic or rhythm complications.
Related Concepts
- heart-failure - Ivabradine is an adjunct option for selected stable HFrEF patients.
- beta-blockers - Both classes reduce heart rate but through different mechanisms.
- digoxin - Another adjunct heart-rate/contractility pathway used in selected contexts.
- systematic-ecg-interpretation-and-dysrhythmia-triage - Rhythm monitoring is central to safe ivabradine use.
Self-Check
- Why is ivabradine not used during acute decompensated heart failure?
- Which rhythm and hemodynamic changes require urgent reassessment after initiation?
- What key food and pregnancy counseling points must be taught before discharge?